| |
Company Fact
 Founded in Feb 2006
Approximately 100 employees
10,000 M2 siRNA drug R&D center, Nantong China
16.6 acre land for future facility, Nantong China
Intellectual Property
Biomics Biotech focusing on RNAi therapeutics research, using our strength on RNAi technologies to continue innovation siRNA drugs development; provides more solutions on diseases which are still hard to treat so that to serve the health needs of society.
Biomics possesses over 40 patents which are categorized as following:
High-throughput siRNA target candidates screening
siRNA drug candidates
Optimized siRNA drug design
(Chemical modification/Multi-targets design)
siRNA delivery system
Small ligand RNA drug candidates
Milestones
March 2012
Britena, whitening anti-blotch cream, manufactured by Gencon Biotech, has been approved as functional cosmetic by SFDA.
October 2011
18 new patents have been filed with total 42 patents of Biomics.
June 2011
Chemical synthesis center has achieved scale up of RNA synthesis, annual capacity has reached to 100 grams.
April 2011
The project of developing cervical cancer diagnosis kit with Zetiq Biotech (Israel) has been approved by the Ministry of Science and Technology of the People's Republic of China.
January 2011
Biomics together with Genecon Biotech, a subsidiary, has been selected as a national siRNA drug incubation center.
November 2010
siRNA-based drug for Aged-related Macular Degeneration (AMD) has launched in pre-clinical safety evaluation stage.
October 2010
Biomics owns 28 patents in total with newly filed 11 key technology patents
.
May 2010
Biomics initiated R&D for RNAi-based drug of bladder cancer and nasopharyngeal cancer.
April 2010
Biomics has agreed to collaborate with Zetiq Biotech (Israel) for developing cervical cancer diagnosis kit.
February 2010
Chemical synthesis center has scaled up to industrial level.
October 2009
Genecon Biotech, a subsidiary of Biomics, is established and the company focuses on commercialization of RNAi-based skin products.
September 2009
Biomics is certified by ISO 9001:2008.
Augus0t 2009
Biomics has agreed to collaborate with Benitec Biopharma (Australia) to develop RNAi drug for Hepatitis B.
January 2009
Biomics has established International Business Department.
December 2008
Biomics scientists have finished R&D of RNAi-drug for Aged-related Macular Degeneration (AMD) via TLR-3 pathway.
October 2008
Biomics has established integrate Quality Control and Quality Analysis system in order to guarantee product quality.
August 2008
Biomics has obtained the siRNA candidates targeting Gene Survivin via Biomics' own technology platform i.e. EsT Library Constructions.
July 2008
Biomics has co-operated with China Pharmaceutical University to develop RNAi drug for liver cancer.
July 2008
Biomics has filed a patent "Construction of pool of interfering nucleic acids covering entire RNA target sequence and related composition".
May 2008
Biomics has established large-scale amidite synthesis workshop.
The application of a new patent, "A Nucleic Acid-Lipid Formulation",has been approved by USPTO.
April 2008
A new patent, "Cationic Lipid Nucleic Acid Salt and Process for Making the Same " has filed to USPTO.
March 2008
New patents, "A Method of Constructing and Preparing Restriction Enzyme Ecop15I" and "Capped Stable Interfering Nucleic Acid Duplexes Having A Nick or Nucleotide Gap in the Sense or Antisense Strands.", have filed applications to USPTO and SIPO respectively.
February 2008
A new patent, "Long Interfering Nucleic Acid Duplexes Having Decreased Interferon Response", has filed to USPTO.
August 2007
Biomics' 10000 m2 R&D labs are ready to use and the company is qualified to manufacture siRNA library, silencing targets screening and siRNA R&D.
July 2007
Biomics warmly welcomes Dr. LU Wei, an AID's vaccine specialist, visiting the company. Biomics and Dr. Lu has agreed to collaborate developing RNAi AID's drugs.
May 2007
Dr. CUI Kunyuan has agreed to join NT Omics, a subsidiary of Biomics Biotech in San Francisco.
December 2006
Biomics' 10000 m2 R&D labs have laid a foundation.
Biomics has received an investment (3.5 M).
October 2006
Biomics scientists have successfully constructed EsT Library for H5N1, SARS and NET-1 viral genes respectively.
August 2006
Biomics website (www.biomics.cn) has gone public.
July 2006
Biomics scientists have successfully constructed long-length genes for H5N1, SARS and HIV.
June 2006
Biomics scientists have constructed cDNA library for organs and tissues.
April 2006
Biomics has established functional groups including protein expression group, PCR group and clone group etc.
February 2006
Biomics Biotechnologies
is founded in E & T Area, Nantong, Jiangsu Province.
|
|
